

<b>Do</b>	<ul style="list-style-type: none"> <li>Do <b>screen for iron deficiency and iron deficiency anemia</b> in patients at risk.<sup>1</sup></li> <li>Do <b>use intravenous (IV) iron</b> when oral iron is not tolerated or ineffective.<sup>1</sup></li> <li>Do refer to your <b>practice setting's clinical decision support tools, protocols, or guidelines</b> specific to IV iron administration.<sup>2</sup></li> <li>Do <b>monitor IV administration</b> before, during, and up to 30 minutes after infusion.<sup>2,3</sup></li> <li>Do <b>recognize infusion reactions</b> and know how to <b>manage</b> them.<sup>2,4</sup></li> <li>Do communicate the <b>symptoms of delayed reactions</b> to patients and how they should be managed.<sup>4</sup></li> </ul>
<b>Stop</b>	<ul style="list-style-type: none"> <li><b>Stop infusion</b> and notify physician or nurse practitioner if patient displays <b>acute symptoms of an infusion reaction</b>.<sup>5</sup></li> </ul>
<b>Consider</b>	<ul style="list-style-type: none"> <li>Consider that the likelihood of <b>anaphylaxis</b> or <b>infusion reactions</b> with IV iron is <b>low</b> but should be weighed against benefits.<sup>6</sup></li> <li>Consider <b>non-sedating antihistamine</b> (e.g., cetirizine) for minor reactions that do not abate when the infusion is discontinued.<sup>7</sup></li> <li>Consider <b>contraindications</b> for each IV preparation.<sup>8</sup></li> </ul>

## Background

Iron deficiency anemia is the most common cause of anemia worldwide. It is characterized by inadequate iron stores or availability, leading to compromised red blood cell production and decreased hemoglobin concentration. Iron deficiency can occur without anemia, but prolonged, untreated deficiency results in iron deficiency anemia.<sup>9</sup>

### *Causes of iron deficiency anemia*<sup>10</sup>

- Increased iron requirements (e.g. pregnancy)
- Low iron intake
- Decreased intestinal iron absorption
- Chronic blood loss
- Multiple causes (absolute iron deficiency associated with inflammation)

### *Signs and symptoms of iron deficiency anemia*<sup>7,11</sup>

- Brittle nails
- Chest pain
- Cold hands or feet
- Dizziness
- Dyspnea
- Extreme fatigue
- Headache
- Inflamed tongue
- Pale skin or conjunctiva
- Palpitations
- Pica
- Reduced appetite
- Weakness

## Objectives of IV Iron Therapy

The aim of treatment for iron deficiency anemia is to replenish iron stores and support red blood cell production.<sup>1,12</sup> IV iron therapy is provided to optimize hemoglobin levels quickly.<sup>13</sup>

## Target Population<sup>2</sup>

Individuals may benefit from the use of IV iron due to:

- Ineffectiveness of or intolerance to oral iron preparations.
- Symptomatic anemia.
- Anticipated inadequate absorption of oral iron (e.g., malabsorption syndrome, certain bariatric surgery procedures).
- Continuous blood loss (e.g., heavy menstrual bleeding, active inflammatory bowel disease).
- Chronic hemodialysis.
- Increased iron demand during pregnancy.
- Certain advanced cancers.
- Time constraints when an increase in hemoglobin or iron repletion for maintaining hemoglobin is required quickly (e.g., preoperatively or prior to labour and delivery).

CITE clinical guidance documents are not clinical practice guidelines; they are CITE's best recommendations based on current knowledge, and no warranty or guaranty is expressed or implied. The content provided is for informational purposes for medical professionals only and is not intended to be used or relied upon by them as specific medical advice, diagnosis, or treatment, the determination of which remains the responsibility of the medical professionals for their patients.

## Currently Used IV Iron Preparations<sup>2,14,15</sup>

Drug	Fe-gluconate <sup>16</sup>	Fe-sucrose <sup>17</sup>	Fe-derisomaltose <sup>18</sup>
<b>Stability</b>	Low	Low-moderate	High
<b>Max. single dose</b>	125 mg	300 mg	20 mg Fe/Kg
<b>Dilution</b>	100 mL of 0.9% NaCl	250 mL of 0.9% NaCl	100 mL–250 mL of 0.9% NaCl
<b>Total replacement dose in single infusion? (1–1.5 g)</b>	No, repeated doses needed	No, repeated doses needed	Yes
<b>Minimum administration time</b>	30–60 mins	30 mins	≤1000 mg: minimum 20 mins >1000 mg: minimum 30 mins
<b>Contraindications</b>	<ul style="list-style-type: none"> <li>All anemias not associated with iron deficiency and where there is evidence of iron overload (e.g., hemochromatosis, chronic hemolysis), or iron utilization disorders (e.g., sideroblastic anemia, lead anemia)</li> <li>Known or suspected hypersensitivity to this drug or any of the excipients</li> <li>Known serious hypersensitivity to other parenteral iron products</li> <li>Severe inflammatory diseases of the liver or kidneys</li> </ul>	<ul style="list-style-type: none"> <li>Evidence of iron overload</li> <li>Known hypersensitivity to this drug or any of the excipients</li> <li>Anemia not caused by iron deficiency</li> </ul>	<ul style="list-style-type: none"> <li>Hypersensitivity to this drug or any of the excipients</li> <li>Known serious hypersensitivity to other parenteral iron products</li> <li>Non-iron deficiency anemia (e.g. hemolytic anemia)</li> <li>Iron overload or disturbances in utilization of iron (e.g. hemochromatosis, hemosiderosis)</li> <li>Decompensated liver cirrhosis or active hepatitis</li> </ul>

## Practical Considerations: Administration of IV Iron<sup>2</sup>

- Assess the patient:
  - Review/obtain patient medical history, including causes for iron deficiency, allergies, or other medications. Obtain baseline vital signs.
  - Review clinical indications and contraindications.
  - Review recent lab test results (*varies by site and region* – complete blood count, ferritin, transferrin saturation).
- Consult with ordering provider if contraindications or other concerns are identified during patient assessment.
- Only administer IV iron in practice settings with immediate access to emergency resuscitation equipment and clinicians trained in emergency response.
- Use of an electronic infusion device, such as a volumetric pump, is strongly recommended.
- Follow your practice setting clinical decision support tools, protocols, or guidelines specific to IV iron administration (if any).
- Once IV iron therapy is started, oral iron may be discontinued on a case-by-case basis. Clarify with your most responsible practitioner.

### MONITORING: BEFORE, DURING, AND UP TO 30 MINUTES AFTER THE END OF IV ADMINISTRATION<sup>2,3,8</sup>

- ✓ Vital signs: blood pressure, heart rate, respiratory rate, oxygen saturation, and temperature
- ✓ Infusion rate
- ✓ Injection site irritation
- ✓ Adverse effects (*see next page*)

### POST-INFUSION INFORMATION TO COMMUNICATE TO PATIENT

- ✓ Patient is required to stay for a 30-minute observation period after the infusion has been completed.<sup>19</sup>
- ✓ Review the main symptoms of a delayed reaction, such as fever, muscle pain, and headache. These symptoms can be treated with acetaminophen, unless contraindicated. Medical attention should be sought if they are not relieved.<sup>2</sup>
- ✓ Communicate any follow-up blood work request, based on physician instructions.<sup>19</sup>
- ✓ Provide information for patient to take home (e.g., patient education pamphlet, website link).<sup>19</sup>

CITE clinical guidance documents are not clinical practice guidelines; they are CITE's best recommendations based on current knowledge, and no warranty or guaranty is expressed or implied. The content provided is for informational purposes for medical professionals only and is not intended to be used or relied upon by them as specific medical advice, diagnosis, or treatment, the determination of which remains the responsibility of the medical professionals for their patients.

## IV Iron Adverse Reactions<sup>4,20,21,22,23,24</sup>


IV iron carries a minimal (1:100-250) risk of inducing a minor infusion reaction that can include flushing, urticaria, pruritus, or chest/back pressure. Severe adverse events are exceedingly rare. Some have estimated the rate of anaphylaxis with IV iron to be less than 1 per 250,000 administrations.<sup>6</sup>

<b>Mild Reactions<sup>15</sup></b>	<b>Fishbane reaction:</b> Self-limited chest/back pain, facial flushing, arthralgias	<b>Severe Reactions<sup>15</sup></b>	<b>Anaphylaxis:</b> Persistent hypotension or angioedema of tongue/airway, OR involvement of $\geq 2$ organ systems: <ul style="list-style-type: none"> <li>• Cardiovascular</li> <li>• Gastrointestinal</li> <li>• Respiratory</li> <li>• Skin</li> </ul>
	<b>Infusion reactions – isolated symptoms:</b> <i>Skin:</i> urticaria, pruritis, periorbital angioedema <i>Respiratory:</i> dyspnea, wheezing, stridor, cough <i>Gastrointestinal:</i> nausea, vomiting, pain, diarrhea		

### WHAT TO LOOK FOR AND WHEN<sup>7</sup>

<b>0 minutes:</b>	Extravasation
<b>&lt;5 minutes:</b>	Fishbane reaction Infusion reactions
<b>5-30 minutes:</b>	Infusion reactions Anaphylaxis
<b>24-72 hours:</b>	Flu-like symptoms Myalgia

## Best Practices: Management of Reaction<sup>15</sup>



CITE clinical guidance documents are not clinical practice guidelines; they are CITE's best recommendations based on current knowledge, and no warranty or guaranty is expressed or implied. The content provided is for informational purposes for medical professionals only and is not intended to be used or relied upon by them as specific medical advice, diagnosis, or treatment, the determination of which remains the responsibility of the medical professionals for their patients.

## References:

- <sup>1</sup> Toward Optimized Practice [Alberta]. Iron deficiency anemia (IDA) Clinical Practice Guideline. Published online March 2018. <https://act.albertadoctors.org/media/tc4lq52r/ida-cpg.pdf>
- <sup>2</sup> INESS. Quebec: National Medical Protocol for Intravenous Iron Therapy in Adults. Published online April 2022. Accessed January 10, 2024. [https://www.inesss.qc.ca/fileadmin/doc/INESSS/Ordonnances\\_collectives/Fer\\_intraveineux/INESSS\\_IV\\_Iron\\_therapy\\_NMP.pdf](https://www.inesss.qc.ca/fileadmin/doc/INESSS/Ordonnances_collectives/Fer_intraveineux/INESSS_IV_Iron_therapy_NMP.pdf)
- <sup>3</sup> European Medicines Agency. New recommendations to manage risk of allergic reactions with intravenous iron-containing medicines. Published online September 13, 2013. Accessed January 17, 2024. [https://www.ema.europa.eu/en/documents/referral/intravenous-iron-containing-medical-products-article-31-referral-new-recommendations-manage-risk-allergic-reactions-intravenous-iron-containing-medicines\\_en.pdf](https://www.ema.europa.eu/en/documents/referral/intravenous-iron-containing-medical-products-article-31-referral-new-recommendations-manage-risk-allergic-reactions-intravenous-iron-containing-medicines_en.pdf)
- <sup>4</sup> Macdougall IC, Bircher AJ, Eckardt KU, et al. Iron management in chronic kidney disease: conclusions from a “Kidney Disease: Improving Global Outcomes” (KDIGO) Controversies Conference. *Kidney International*. 2016;89(1):28-39. doi:[10.1016/j.kint.2015.10.002](https://doi.org/10.1016/j.kint.2015.10.002)
- <sup>5</sup> Richards T, Breyman C, Brookes MJ, et al. Questions and answers on iron deficiency treatment selection and the use of intravenous iron in routine clinical practice. *Ann Med*. 2021;53(1):274-285. doi:10.1080/07853890.2020.1867323
- <sup>6</sup> Arastu AH, Elstrott BK, Martens KL, et al. Analysis of Adverse Events and Intravenous Iron Infusion Formulations in Adults With and Without Prior Infusion Reactions. *JAMA Netw Open*. 2022;5(3):e224488. doi:[10.1001/jamanetworkopen.2022.4488](https://doi.org/10.1001/jamanetworkopen.2022.4488)
- <sup>7</sup> Cooper M, Greene-Finestone L, Lowell H, Levesque J, Robinson S. Iron sufficiency of Canadians. *Health Rep*. 2012;23(4):41-48
- <sup>8</sup> Edwards S, Axe S. The 10 ‘R’s of safe multidisciplinary drug administration. *Nurse Prescribing*. 2015;13(8):398-406. doi:[10.12968/npre.2015.13.8.398](https://doi.org/10.12968/npre.2015.13.8.398)
- <sup>9</sup> Archived: Iron Deficiency Anaemia: Assessment, Prevention and Control. World Health Organization. 2001. Accessed January 17, 2024. <https://www.who.int/publications/m/item/iron-children-6to23--archived-iron-deficiency-anaemia-assessment-prevention-and-control>
- <sup>10</sup> Camaschella C. Iron deficiency. *Blood*. 2019;133(1):30-39. doi:[10.1182/blood-2018-05-815944](https://doi.org/10.1182/blood-2018-05-815944)
- <sup>11</sup> Johnson-Wimbley TD, Graham DY. Diagnosis and management of iron deficiency anemia in the 21st century. *Therap Adv Gastroenterol*. 2011;4(3):177-184. doi:[10.1177/1756283X11398736](https://doi.org/10.1177/1756283X11398736)
- <sup>12</sup> Goddard AF, James MW, McIntyre AS, Scott BB. Guidelines for the management of iron deficiency anaemia. *Gut*. 2011;60(10):1309-1316. doi:[10.1136/gut.2010.228874](https://doi.org/10.1136/gut.2010.228874)
- <sup>13</sup> Gozzard D. When is high-dose intravenous iron repletion needed? Assessing new treatment options. *Drug Des Devel Ther*. 2011;5:51-60. doi:[10.2147/DDDT.S15817](https://doi.org/10.2147/DDDT.S15817)
- <sup>14</sup> Girelli D, Ugolini S, Busti F, Marchi G, Castagna A. Modern iron replacement therapy: clinical and pathophysiological insights. *Int J Hematol*. 2018;107(1):16-30. doi:[10.1007/s12185-017-2373-3](https://doi.org/10.1007/s12185-017-2373-3)
- <sup>15</sup> Lim W, Afif W, Knowles S, et al. Canadian expert consensus: management of hypersensitivity reactions to intravenous iron in adults. *Vox Sanguinis*. 2019;114(4):363-373. doi:[10.1111/vox.12773](https://doi.org/10.1111/vox.12773)
- <sup>16</sup> sanofi-aventis Canada Inc. FERRLECIT® Sodium Ferric Gluconate Complex in Sucrose Injection PRODUCT MONOGRAPH. In: 2016:37. Accessed January 16, 2024. [https://pdf.hres.ca/dpd\\_pm/00054289.PDF](https://pdf.hres.ca/dpd_pm/00054289.PDF)
- <sup>17</sup> American Regent, Inc. MONOFERRIC (ferric derisomaltose) Iron Sucrose Injection, USP (Venofer) PRODUCT MONOGRAPH. In: Shirley, New York; 2019:29. Accessed January 17, 2024. <https://webfiles.pfizer.com/file/645d5e9f-8730-4715-9c74-fdb0e759cb96?referrer=ccb731e5-4f2d-4f4a-b2dc-e5e912145fc6>
- <sup>18</sup> Pfizer Canada ULC. PrMONOFERRIC® Ferric Derisomaltose for Injection. In: ; 2022:40. Accessed January 17, 2024. <https://webfiles.pfizer.com/file/645d5e9f-8730-4715-9c74-fdb0e759cb96?referrer=ccb731e5-4f2d-4f4a-b2dc-e5e912145fc6>
- <sup>19</sup> Adapted from Tascona content collection tool submission, Venofer Patient education pamphlet, & IV iron therapy pamphlet - periop
- <sup>20</sup> Achebe M, DeLoughery TG. Clinical data for intravenous iron – debunking the hype around hypersensitivity. *Transfusion*. 2020;60(6):1154-1159. doi:[10.1111/trf.15837](https://doi.org/10.1111/trf.15837)
- <sup>21</sup> Rampton D, Folkersen J, Fishbane S, et al. Hypersensitivity reactions to intravenous iron: guidance for risk minimization and management. *Haematologica*. 2014;99(11):1671-1676. doi:[10.3324/haematol.2014.111492](https://doi.org/10.3324/haematol.2014.111492)
- <sup>22</sup> Cardona V, Ansotegui IJ, Ebisawa M, et al. World Allergy Organization Anaphylaxis Guidance 2020. *World Allergy Organization Journal*. 2020;13(10). doi:[10.1016/j.waojou.2020.100472](https://doi.org/10.1016/j.waojou.2020.100472)
- <sup>23</sup> Fishbane S, Ungureanu VD, Maesaka JK, Kaupke CJ, Lim V, Wish J. The safety of intravenous iron dextran in hemodialysis patients. *Am J Kidney Dis*. 1996;28(4):529-534. doi:[10.1016/s0272-6386\(96\)90463-1](https://doi.org/10.1016/s0272-6386(96)90463-1)
- <sup>24</sup> Coyne DW, Adkinson NF, Nissenson AR, et al. Sodium ferric gluconate complex in hemodialysis patients. II. Adverse reactions in iron dextran-sensitive and dextran-tolerant patients. *Kidney Int*. 2003;63(1):217-224. doi:[10.1046/j.1523-1755.2003.00703.x](https://doi.org/10.1046/j.1523-1755.2003.00703.x)

CITE clinical guidance documents are not clinical practice guidelines; they are CITE’s best recommendations based on current knowledge, and no warranty or guaranty is expressed or implied. The content provided is for informational purposes for medical professionals only and is not intended to be used or relied upon by them as specific medical advice, diagnosis, or treatment, the determination of which remains the responsibility of the medical professionals for their patients.